DSpace Repositorium (Manakin basiert)

Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease

Zur Kurzanzeige

dc.contributor.author Saposnik, Gustavo
dc.contributor.author Sánchez-Benavidez, Gonzalo
dc.contributor.author García-Arcelay, Elena
dc.contributor.author Franco-Macías, Emilio
dc.contributor.author Bensi, Catalina
dc.contributor.author Carmelingo, Sebastián
dc.contributor.author Allegri, Ricardo Francisco
dc.contributor.author Pérez-Martíne, David A.
dc.contributor.author Maurino, Jorge
dc.date.accessioned 2023-12-11T16:51:30Z
dc.date.available 2023-12-11T16:51:30Z
dc.date.issued 2023-03-23
dc.identifier.citation Saposnik, G., Sánchez-Benavidez, G., García-Arcelay, E., Franco-Macías, E., Bensi, C., Carmelingo, S., Allegri, R.F., Pérez-Martínez, D.A., Maurino, J., 2023. Design of a Non-Interventional Study to Assess Neurologists’ Perspectives and Pharmacological Treatment Decisions in Early Alzheimer’s Disease. Neurol Ther. https://doi.org/10.1007/s40120-023-00466-9 es_ES
dc.identifier.uri https://doi.org/10.1007/s40120-023-00466-9
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/903
dc.description.abstract Introduction: The current therapeutic landscape of Alzheimer's disease (AD) is evolving rapidly. Our treatment options include new anti-amyloid-β protein disease-modifying therapies (DMTs) that decrease cognitive decline in patients with early AD (prodromal and mild AD dementia). Despite these advances, we have limited information on how neurologists would apply the results of recent DMT trials to make treatment decisions. Our goal is to identify factors associated with the use of new AD DMTs among neurologists applying concepts from behavioral economics. Methods: This non-interventional, cross-sectional, web-based study will assess 400 neurologists with expertise in AD from across Spain. Participants will start by completing demographic information, practice settings, and a behavioral battery to address their tolerance to uncertainty and risk preferences. Participants will then be presented with 10 simulated case scenarios or vignettes of common encounters in patients with early AD to evaluate treatment initiation with anti-amyloid-β DMTs (e.g., aducanumab, lecanemab, etc.). The primary outcomes will be therapeutic inertia and suboptimal decisions. Discrete choice experiments will be used to determine the weight of factors influencing treatment choices. Results: The results of this study will provide new insights into a better understanding of the most relevant factors associated with therapeutic decisions on the use of DMTs, assessing how neurologists handle uncertainty when making treatment choices, and identifying the prevalence of therapeutic inertia in the management of early AD. es_ES
dc.language.iso eng es_ES
dc.publisher Springer es_ES
dc.subject Alzheimer Disease es_ES
dc.subject Enfermedad de Alzheimer es_ES
dc.subject Decision Making es_ES
dc.subject Toma de Decisiones es_ES
dc.title Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.description.fil Fil: Allegri, Ricardo Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina.
dc.relation.ispartofVOLUME 12
dc.relation.ispartofNUMBER 3
dc.relation.ispartofPAGINATION 995-1006
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Nueva York
dc.relation.ispartofTITLE Neurology and therapy
dc.relation.ispartofISSN 2193-6536
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Dateien zu dieser Ressource

Das Dokument erscheint in:

Zur Kurzanzeige

DSpace Suche


Stöbern

Mein Benutzerkonto

Statistik